The DOI matches its Crossref record.
Adenosine A 2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function
Open accessAbstract
Adenosine is an immunosuppressive nucleoside, and adenosine A 2A receptors inhibit T‐cell activation. We investigated the role of A 2A receptors in regulating T helper (Th)1‐ and Th2‐cell development and effector function. A 2A ‐receptor stimulation suppressed the development of T‐cell receptor (TCR) ‐stimulated naive T cells into both Th1 and Th2 cells, as indicated by decreased IFN‐γ production by cells developed under Th1‐skewing conditions and decreased interleukin (IL) −4, IL5, and IL10 production by cells developed under Th2‐skewing conditions. Using A 2A receptor‐deficient mice, we demonstrate that A 2A receptor activation inhibits Th1‐ and Th2‐cell development by decreasing the proliferation and IL2 production of naive T cells, irrespective of whether the cells are expanded under Th1‐ or Th2‐skewing environment. Using in vivo established Th1 and Th2 cells, we further demonstrate the nonselective nature of A 2A receptor‐mediated immunosuppressive effects, because A 2A receptor activation decreased IFN‐γ and IL4 secretion and mRNA level of TCR‐stimulated effector Th1 and Th2 cells, respectively. A 2A receptor mRNA expression in both Th1 and Th2 effector cells increased following TCR stimulation. In summary, these data demonstrate that A 2A receptor activation has strong inhibitory actions during early developmental, as well as late effector, stages of Th1‐ and Th2‐cell responses.—Csóka, B., Himer, L., Selmeczy, Z., Vizi, E. S., Pacher, P., Ledent, C., Deitch, E. A., Spolarics, Z., Németh, Z. H., Haskó, G. Adenosine A 2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function. FASEB J. 22, 3491–3499 (2008)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
Mager, L. F., Burkhard, R., Pett, N., Cooke, N. C. A., Brown, K., Ramay, H., Paik, S., Stagg, J., Groves, R. A., Gallo, M., et al. (2020) · Science · doi:10.1126/science.abc3421 · Cited by 1,407
Adenosine receptors: therapeutic aspects for inflammatory and immune diseases
Haskó, G., Linden, J., Cronstein, B., & Pacher, P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2638 · Cited by 1,217
Self-citationMechanisms of allergen-specific immunotherapy
Akdis, C. A., & Akdis, M. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.11.030 · Cited by 803
Immunity, inflammation and cancer: a leading role for adenosine
Antonioli, L., Blandizzi, C., Pacher, P., & Haskó, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3613 · Cited by 765
Self-citationThe adenosine pathway in immuno-oncology
Allard, B., Allard, D., Buisseret, L., & Stagg, J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0382-2 · Cited by 586
Extracellular adenosine triphosphate and adenosine in cancer
Stagg, J., & Smyth, M. J. (2010) · Oncogene · doi:10.1038/onc.2010.292 · Cited by 571
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
Vigano, S., Alatzoglou, D., Irving, M., Ménétrier-Caux, C., Caux, C., Romero, P., & Coukos, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00925 · Cited by 420
CD39/CD73/A2AR pathway and cancer immunotherapy
Xia, C., Yin, S., To, K. K. W., & Fu, L. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01733-x · Cited by 399
Role of Treg in immune regulation of allergic diseases
Palomares, O., Yaman, G., Azkur, A. K., Akkoc, T., Akdis, M., & Akdis, C. A. (2010) · European Journal of Immunology · doi:10.1002/eji.200940045 · Cited by 394
A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment
Young, A., Ngiow, S. F., Gao, Y., Patch, A.-M., Barkauskas, D. S., Messaoudene, M., Lin, G., Coudert, J. D., Stannard, K. A., Zitvogel, L., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2826 · Cited by 391
Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens
Akdis, C. A., & Akdis, M. (2015) · World Allergy Organization Journal · doi:10.1186/s40413-015-0063-2 · Cited by 361
Mechanisms and treatment of allergic disease in the big picture of regulatory T cells
Akdis, C. A., & Akdis, M. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.02.030 · Cited by 337
Purinergic signalling and immune cells
Burnstock, G., & Boeynaems, J.-M. (2014) · Purinergic Signalling · doi:10.1007/s11302-014-9427-2 · Cited by 309
Cekic, C., Day, Y.-J., Sag, D., & Linden, J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3583 · Cited by 304
Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases
Cronstein, B. N., & Sitkovsky, M. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.178 · Cited by 258
He, B., Hoang, T. K., Wang, T., Ferris, M., Taylor, C. M., Tian, X., Luo, M., Tran, D. Q., Zhou, J., Tatevian, N., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20160961 · Cited by 196
“the therapeutic effect of inosine on t reg cell–deficient SF mice is mediated by A2A receptors T reg cells control Th1/Th2 mediated by A2A receptors (Deaglio et al., 2007; Csóka et al., 2008; Antonioli et al., 2013).”
BackgroundInfluential
Metadata
- Authors
- Csóka, B., Himer, L., Selmeczy, Z., Vizi, E. S., Pacher, P., Ledent, C., Deitch, E. A., Spolarics, Z., Németh, Z. H., & Haskü, G.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2008-07-14
- Volume
- 22
- Issue
- 10
- Pages
- 3491-3499
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2001776200
- Cited by
- 197
- References
- 0
- FWCI
- 5.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.